source
- FDA clears Click Therapeutics' Motivista, first digital therapeutic for negative schizophrenia symptomsClick Therapeutics received FDA 510(k) clearance for its digital therapeutic, Motivista (formerly CT-155), marking the first authorized treatment targeting negative symptoms of schizophrenia in the…
- PTC Therapeutics agrees to pay up to $211 million for Sangamo’s experimental Fabry disease gene therapyPTC Therapeutics announced it will invest up to $211 million to acquire rights to an advanced gene therapy for Fabry disease being developed by Sangamo Therapeutics. The therapy, called ST-920 (is…